{
    "nctId": "NCT01093235",
    "briefTitle": "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer",
    "officialTitle": "ARTemis - Avastin Randomized Trial With Neo-Adjuvant Chemotherapy for Patients With Early Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 800,
    "primaryOutcomeMeasure": "Complete pathological response rates (tumor and lymph nodes)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer\n* HER2-negative disease\n\n  * IHC 0/1 OR IHC 2+ and FISH negative\n* Must meet 1 of the following criteria:\n\n  * Unifocal tumor meeting 1 of the following criteria:\n\n    * T2 or T3 tumors (radiological size \\> 20 mm)\n    * T4 tumor of any size with direct extension to the chest wall or the skin\n    * Inflammatory carcinoma with tumor of any size\n  * Multifocal tumor meeting the following criteria:\n\n    * The sum of each tumors' maximum diameter must be \u2265 20 mm (total radiological tumor size \u2265 20 mm)\n  * Other locally advanced disease meeting 1 of the following criteria:\n\n    * Any T stage with involvement of large or fixed axillary lymph nodes (radiological diameter \\> 20 mm or clinical N2) and primary breast tumor of any diameter\n    * Any T stage with involvement of large or fixed axillary lymph nodes (radiological diameter \\> 20 mm or clinical N2), without a primary breast tumor identified and the presence of breast cancer in a lymph node must be histopathologically confirmed by lymph node biopsy (tru-cut or whole lymph node)\n* Embedded paraffin tumor block available from pre-chemotherapy biopsy and surgical specimen\n* Bilateral disease allowed\n* No evidence of metastatic disease\n* No prior breast cancer except for ductal carcinoma in situ of the breast surgically cured \\> 10 years ago\n* Any hormone receptor status\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* WBC \\> 3 x 10\\^9/L\n* Hemoglobin \\> 10 g/dL\n* Platelet count \\> 100 x 10\\^9/L\n* AST/ALT \u2264 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2 times ULN\n* Bilirubin normal\n\n  * Isolated elevation of bilirubin to \u2264 3 times ULN with a presumptive diagnosis of Gilbert syndrome allowed if AST/ALT and alkaline phosphatase are within normal limits\n* Creatinine \u2264 1.5 times ULN\n* PT and PTT/aPTT \u2264 1.5 times ULN\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective barrier contraception\n* Must be fit to receive chemotherapy on this trial, in the opinion of the responsible clinician, as indicated by the following criteria:\n\n  * No clinically significant cardiac abnormalities\n  * No myocardial infarction within the past 6 months\n  * LVEF normal (at least 50%) by MUGA scan or echocardiogram\n* No prior ischemic heart disease, cerebrovascular disease, peripheral vascular disease, arterial or venous thromboembolic disease, cardiac failure, inflammatory bowel disease, gastroduodenal ulcer, symptomatic diverticulitis, or bleeding diathesis\n* No uncontrolled hypertension (systolic BP \\> 150 mm Hg or diastolic BP \\> 90 mm Hg) with or without antihypertensive medication\n\n  * Patients with initial blood pressure elevations are eligible provided initiation or adjustment of antihypertensive medication lowers pressure to meet entry criteria\n* No other previous malignancy except basal cell carcinoma, carcinoma in situ of the cervix, or ductal carcinoma in situ of the breast treated by surgery only and disease-free for 10 years\n* No concurrent medical or psychiatric problem that might prevent completion of treatment or follow-up\n* No presence of active uncontrolled infection\n* No history of nephritic or nephrotic syndrome\n* No traumatic injury within the past 28 days\n* No evidence of other disease that, in the opinion of the investigator, places the patient at high risk of treatment-related complications\n* No nonhealing wound, peptic ulcer, or bone fracture\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior neoadjuvant endocrine therapy\n* No prior chemotherapy or radiotherapy\n* No major surgical procedure within the past 28 days\n* No concurrent full therapeutic dose of anticoagulants or aspirin \\> 325 mg/day, clopidogrel \\> 75 mg/day, or corticosteroids",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}